MedTrace Logo

Short-course Methenamine Hippurate for Prevention of Post-operative UTI

NCT02358993 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2022-02-25

Study results available
· View outcomes & findings →

Summary

The investigators will determine the efficacy of an innovative short regimen of methenamine hippurate on prevention of post-operative UTI in patients requiring short-term catheterization after pelvic reconstructive surgery through a single-blind, randomized controlled trial. Primary outcome will be the rate of symptomatic UTI within 3 weeks of catheter removal. The investigators will study cost-effectiveness, antibiotic resistance profiles, and adverse drug effects. Findings may reduce antibiotic use and nosocomial UTIs.

Conditions

Interventions

DRUG

methenamine hippurate

A urinary antiseptic used for prevention of UTI

DRUG

Ciprofloxacin

An antibiotic used for treatment and prevention of UTI

Sponsors & Collaborators

Principal Investigators

  • Christine M Chu, MD · University of Pennsylvania

  • Lily Arya, MD, MS · University of Pennsylvania

  • Daniel Lee, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02358993 on ClinicalTrials.gov